Feature

How to Reduce Cardiovascular Morbidity and Mortality in Psoriasis and PsA


 

Beyond traditional risk elevation, the primary care hand-off

Rheumatologists “in general may be more apt to screen for cardiovascular disease” as a result of their internal medicine residency training, and “we’re generally more comfortable prescribing ... if we need to,” said Alexis R. Ogdie, MD, a rheumatologist at the Hospital of the University of Pennsylvania, Philadelphia, and director of the Penn Psoriatic Arthritis Clinic.

Dr. Alexis R. Ogdie-Beatty, director of the psoriatic arthritis clinic, and Dr. Joel M. Gelfand, professor of dermatology, at University of Pennsylvania, Philadelphia. Penn Medicine

Dr. Alexis R. Ogdie-Beatty, director of the psoriatic arthritis clinic, and Dr. Joel M. Gelfand, professor of dermatology, at University of Pennsylvania, Philadelphia.

Referral to a preventive cardiologist for management of abnormal lab results or ongoing monitoring and prevention is ideal, but when hand-offs to primary care physicians are made — the more common scenario — education is important. “A common problem is that there is underrecognition of the cardiovascular risk being elevated in our patients,” she said, above and beyond risk posed by traditional risk factors such as dyslipidemia, hypertension, metabolic syndrome, and obesity, all of which have been shown to occur more frequently in patients with psoriatic disease than in the general population.

Standard screening recommendations

Risk stratification guides CVD prevention in the general population, and “if you use typical scores for cardiovascular risk, they may underestimate risk for our patients with PsA,” said Dr. Ogdie, who has reported on CV risk in patients with PsA. “Relative to what the patient’s perceived risk is, they may be treated similarly (to the general population). But relative to their actual risk, they’re undertreated.”

The 2019 AAD-NPF psoriasis guidelines recommend utilizing a 1.5 multiplication factor in risk score models, such as the American College of Cardiology’s Atherosclerotic Cardiovascular Disease (ASCVD) Risk Estimator, when the patient has a body surface area >10% or is a candidate for systemic therapy or phototherapy.

Similarly, the 2018 American Heart Association (AHA)-ACC Guideline on the Management of Blood Cholesterol defines psoriasis, along with RA, metabolic syndrome, HIV, and other diseases, as a “cardiovascular risk enhancer” that should be factored into assessments of ASCVD risk. (The guideline does not specify a psoriasis severity threshold.)

“It’s the first time the specialty [of cardiology] has said, ‘pay attention to a skin disease,’ ” Dr. Gelfand said at the NPF meeting.

Using the 1.5 multiplication factor, a patient who otherwise would be classified in the AHA/ACC guideline as “borderline risk,” with a 10-year ASCVD risk of 5% to <7.5%, would instead have an “intermediate” 10-year ASCVD risk of ≥7.5% to <20%. Application of the AHA-ACC “risk enhancer” would have a similar effect.

For management, the main impact of psoriasis being considered a risk enhancer is that “it lowers the threshold for treatment with standard cardiovascular prevention medications such as statins.”

In general, “we should be taking a more aggressive approach to the management of traditional cardiovascular risk factors” in patients with psoriatic disease, he said. Instead of telling a patient with mildly elevated blood pressure, ‘I’ll see you in a year or two,’ or a patient entering a prediabetic stage to “watch what you eat, and I’ll see you in a couple of years,” clinicians need to be more vigilant.

Doctor talking with male patient Morsa Images/DigitalVision/Getty Images

A doctor talks to a patient

“It’s about recognizing that these traditional cardiometabolic risk factors, synergistically with psoriasis, can start enhancing CV risk at an earlier age than we might expect,” said Dr. Garshick, whose 2021 review of CV risk in psoriasis describes how the inflammatory milieu in psoriasis is linked to atherosclerosis development.

Cardiologists are aware of this, but “many primary care physicians are not. It takes time for medical knowledge to diffuse,” Dr. Gelfand said. “Tell the PCP, in notes or in a form letter, that there is a higher risk of CV disease, and reference the AHA/ACC guidelines,” he advised. “You don’t want your patient to go to their doctor and the doctor to [be uninformed].”

Recommended Reading

Review finds no CV or VTE risk signal with use of JAK inhibitors for skin indications
MDedge Rheumatology
FDA OKs first ustekinumab biosimilar
MDedge Rheumatology
Most patients with psoriasis not engaged in highly shared decision-making
MDedge Rheumatology
Researchers tease apart multiple biologic failure in psoriasis, PsA
MDedge Rheumatology
Review estimates acne risk with JAK inhibitor therapy
MDedge Rheumatology
The challenges of palmoplantar pustulosis and other acral psoriatic disease
MDedge Rheumatology
TNF blockers not associated with poorer pregnancy outcomes
MDedge Rheumatology
Nail psoriasis in Black patients often overlooked
MDedge Rheumatology
Low-dose methotrexate carries higher risk for older patients with CKD
MDedge Rheumatology
Bimekizumab shows promise for palmoplantar pustular psoriasis
MDedge Rheumatology